▲ Up
 
04:35 23-01-2017
MAIN АКИpress CA-News
About us On-line subscription
KazakhstanKyrgyzstanMongoliaTajikistanTurkmenistanUzbekistanWorld
POLITICSBUSINESSINCIDENTSSOCIETYCULTURESPORTANALYSISSCIENCE
Drug to crack resistant TB
13:01, 25 March 2014, 1435

AKIPRESS.COM - doctor-x-ray Florian von Groote-Bidlingmaier, medical director of TASK Applied Science, a research unit collaborating with Stellenbosch University, told doctors yesterday about trials of new drugs that might offer a lifeline to patients with drug-resistant TB, Times Live reported.

He was speaking at the World TB Day Symposium, convened by the National Institute for Communicable Diseases, in Johannesburg.

Half-a-million South Africans contract TB every year and one in 25 is likely to develop a form of the disease resistant to treatment. Drug-resistant TB kills at least one in five of the people who contract it.

Most TB drugs have been in use for at least 50 years, Von Groote-Bidlingmaier said, but the development of a new medicine took many years and could cost as much as 10 billion rand ($920.3 million).

It can be years before patients gain access to a new medicine. For example, the drug bedaquiline was developed in 2005 but almost 10 years later it is available to only 200 patients in South Africa in a monitored program with strict eligibility criteria.

Von Groote-Bidlingmaier said that delamanid, conditionally approved by the European Medicines Agency recently, was being tested at three sites in South Africa and abroad. The current trials, if successful, are the last step before the drug is registered.

“TB is not treated with a single drug. There is a need for further trials to test new drugs in combination to see if we can find a better treatment regimen.”

South Africa is the world leader in the exploitation of the GeneXpert machine to detect TB much more quickly. But a study has shown that, though detection has improved, patients are no more likely to start and see their treatment through to completion.

TASK Applied Science performs clinical trials in tuberculosis (TB) in Cape Town, South Africa. TASK can provide assistance to efficiently conduct studies for diagnosis, treatment or prevention of tuberculosis.


Twitterfacebookprint
LATEST NEWS
16:34 Belarus plans to exchange space information with Kazakhstan16:05 Kyrgyz Customs Service collects customs duties for 2.8 billion soms less in 2016 than planned15:45 Kazakhstan orders new curbs on Internet use14:51 Clearing of cargo plane crash scene ongoing outside Bishkek14:08 Turkmenistan eyes export of electricity via Afghanistan13:48 Foreign Ministry highlights changes in Kyrgyz student visa procedures for domestic universities13:31 Kazakhstan confirms H5 bird flu in wild swans13:27 US beef master class showcases alternative cuts for Uzbekistan chefs13:24 Over 19 million soms transferred in donations to special account for plane crash victims13:18 Pioneering clinical trial for drug-resistant tuberculosis starts in Uzbekistan12:49 Ten pulled alive from avalanche hotel in Italy after snow created 'igloo'12:43 Police injured, more than 200 arrested at Trump inauguration protests in DC12:36 President Atambayev tasks Emergency Ministry to focus on support to be provided to families of plane crash victims12:27 Proposed railway from China to Uzbekistan to link Kyrgyzstan's north and south12:17 Preliminary analysis of unsealed flight data recorder finds air accident information12:00 Visit of IMF 'rescue' team to Mongolia delayed11:59 President Atambayev offers condolences to Iran over deadly fire, collapse of Tehran high-rise building11:31 Mongolia to increase its gold reserves11:24 EBRD designates Bishkek as hub for Central Asia – Regional Director11:04 Trump pursues 'new vision' on first day as president
© AKIpress News Agency - 2001-2017. All rights reserved
Republication of any material is prohibited without a written agreement with AKIpress News Agency. Any citation must be accompanied by a hyperlink to akipress.com.
Our address:
Moskovskaya str. 189, Bishkek, the Kyrgyz Republic
e-mail: english@akipress.org, akipressenglish@gmail.com;
Tel/Fax: +996(312)90-07-75